WallStSmart
MXCT

MaxCyte Inc

NASDAQ: MXCT · HEALTHCARE · MEDICAL DEVICES

$0.84
-3.24% today

Updated 2026-05-08

Market cap
$90.34M
P/E ratio
P/S ratio
2.74x
EPS (TTM)
$-0.42
Dividend yield
52W range
$1 – $2
Volume
0.9M

MaxCyte Inc (MXCT) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+6.1%
Last 4 quarters
Revenue YoY growth
-16.0%
Most recent quarter
EPS YoY growth
+43.4%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-6.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-9.9%
2026-03-17
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-17$-0.06+27.4%$0.81$0.73-9.9%
2025-11-12$-0.12-5.9%$1.55$1.51-2.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.08$-0.06+27.4%$7.30M-16.0%
2025-09-30$-0.11$-0.12-5.9%$6.83M-16.4%
2025-06-30$-0.10$-0.12-20.0%$8.51M-18.4%
2025-03-31$-0.13$-0.10+23.1%$10.39M-8.4%
2024-12-31$-0.12$-0.10+16.7%$8.69M-44.5%
2024-09-30$-0.12$-0.11+8.3%$8.16M+2.0%
2024-06-30$-0.13$-0.09+30.8%$10.43M+15.3%
2024-03-31$-0.13$-0.09+30.8%$11.34M+32.3%
2023-12-31$-0.07$-0.05+28.6%$15.66M
2023-09-30$-0.10$-0.11-10.0%$8.00M
2023-06-30$-0.10$-0.10+0.0%$9.04M
2023-03-31$-0.11$-0.11+0.0%$8.58M

Frequently asked questions

Has MaxCyte Inc beaten earnings estimates?
MaxCyte Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +6.1% over the last 4 quarters.
How does MXCT stock react to earnings?
MXCT stock has moved an average of -6.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is MaxCyte Inc's revenue growth rate?
MaxCyte Inc reported year-over-year revenue growth of -16.0% in its most recent quarter, with EPS growing +43.4% year-over-year.